Literature DB >> 12612977

Steroid-sensitive nephrotic syndrome: from childhood to adulthood.

Fadi Fakhouri1, Nathalie Bocquet, Pierre Taupin, Claire Presne, Marie-France Gagnadoux, Paul Landais, Philippe Lesavre, Dominique Chauveau, Bertrand Knebelmann, Michel Broyer, Jean-Pierre Grünfeld, Patrick Niaudet.   

Abstract

BACKGROUND: The clinical presentation, treatment, and outcome of steroid-sensitive nephrotic syndrome (SSNS) during childhood have been extensively studied. Conversely, few data regarding the outcome in adulthood of childhood SSNS have been published previously. We undertook to conduct a retrospective study of the outcome in adulthood of a large cohort of patients diagnosed with an SSNS during childhood.
METHODS: We identified all children born between 1970 and 1975 who had been admitted to our institution for an SSNS. Data regarding the outcome in adulthood of these patients were obtained through mailed questionnaires or phone calls to patients and/or their parents or through attending physicians.
RESULTS: One hundred seventeen patients were identified. Data regarding the outcome of SSNS in adulthood were available for 102 patients (87.2%). Forty-three patients (42.2%) experienced at least one relapse of nephrotic syndrome in adulthood. By univariate analysis, young age at onset (<6 years) and more severe disease in childhood, indicated by a greater number of relapses (12.9 for adulthood relapsers versus 5.4 for adulthood nonrelapsers; P < 0.0001) and more frequent use of immunosuppressors (74.4% versus 31.6%; P < 0.0001) or cyclosporine (42.9% versus 7.3%; P < 0.0001) were predictive of the occurrence of SSNS relapse in adulthood. Conversely, relapse rate in the first 6 months of disease was not predictive of further relapses in adulthood. By multivariate analysis, only number of relapses during childhood was predictive of adulthood relapses (P < 0.0058). Long-term side effects of steroids were found in 44.2% of adulthood relapsers; the most frequent were osteoporosis and excess weight.
CONCLUSION: The incidence of childhood SSNS relapses in adulthood was relatively high in our study. Further studies are required to assess long-term complications in adults with relapses and a history of prolonged steroid and immunosuppressor use. Copyright 2003 by the National Kidney Foundation, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12612977     DOI: 10.1053/ajkd.2003.50116

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  58 in total

1.  Pediatrics: how 'minimal' are the adult consequences of childhood MCNS?

Authors:  Kevin V Lemley
Journal:  Nat Rev Nephrol       Date:  2010-02       Impact factor: 28.314

2.  Body weight-based prednisolone versus body surface area-based prednisolone regimen for induction of remission in children with nephrotic syndrome: a randomized, open-label, equivalence clinical trial.

Authors:  Vaishnavi Raman; Sriram Krishnamurthy; K T Harichandrakumar
Journal:  Pediatr Nephrol       Date:  2016-01-12       Impact factor: 3.714

Review 3.  Evidence-based management of steroid-sensitive nephrotic syndrome.

Authors:  Elisabeth M Hodson; Jonathan C Craig; Narelle S Willis
Journal:  Pediatr Nephrol       Date:  2005-06-21       Impact factor: 3.714

4.  Clinical features and outcome of childhood minimal change nephrotic syndrome: is genetics involved?

Authors:  Anne-Tiina Lahdenkari; Maija Suvanto; Eero Kajantie; Olli Koskimies; Marjo Kestilä; Hannu Jalanko
Journal:  Pediatr Nephrol       Date:  2005-06-21       Impact factor: 3.714

5.  The impact of pediatric nephrotic syndrome on families.

Authors:  Sulagna Mitra; Sushmita Banerjee
Journal:  Pediatr Nephrol       Date:  2011-05-29       Impact factor: 3.714

6.  Clinical practice guideline for pediatric idiopathic nephrotic syndrome 2013: general therapy.

Authors:  Yoshitsugu Kaku; Yasufumi Ohtsuka; Yasuhiro Komatsu; Toshiyuki Ohta; Takuhito Nagai; Hiroshi Kaito; Shuji Kondo; Yohei Ikezumi; Seiji Tanaka; Shinsuke Matsumoto; Mayumi Sako; Kazushi Tsuruga; Koichi Nakanishi; Koichi Kamei; Hiroshi Saito; Shuichiro Fujinaga; Yuko Hamasaki; Hiroko Chikamoto; Kenji Ishikura; Kazumoto Iijima
Journal:  Clin Exp Nephrol       Date:  2015-02       Impact factor: 2.801

Review 7.  Rituximab and minimal change nephrotic syndrome: a therapeutic option.

Authors:  Takashi Takei; Kosaku Nitta
Journal:  Clin Exp Nephrol       Date:  2011-05-26       Impact factor: 2.801

8.  Rituximab therapy for steroid-dependent minimal change nephrotic syndrome.

Authors:  Rodney D Gilbert; Eleanor Hulse; Susan Rigden
Journal:  Pediatr Nephrol       Date:  2006-08-24       Impact factor: 3.714

9.  The risk of cardiovascular disease in adults who have had childhood nephrotic syndrome.

Authors:  Brent Lee Lechner; Detlef Bockenhauer; Sandra Iragorri; Thomas Lyle Kennedy; Norman Joseph Siegel
Journal:  Pediatr Nephrol       Date:  2004-04-15       Impact factor: 3.714

Review 10.  Minimal Change Disease.

Authors:  Marina Vivarelli; Laura Massella; Barbara Ruggiero; Francesco Emma
Journal:  Clin J Am Soc Nephrol       Date:  2016-12-09       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.